Stem Cell Series Episode 4: Clinical Translation of Gene-Edited Hematopoietic Stem Cells for β-Thalassemia and Product Pipeline Overview

Jul 23, 2024 07:31 CST Updated 07:31

BRL Medicine

Cell and Gene Therapy Drug Developer

【Preview of the 4th Online Open Course】

Guest Profile

Dr. Zheng Biao

Senior Partner and CEO of BRL Medicine

Dr. Zheng Biao graduated from the Department of Medicine, Zhejiang University School of Medicine; obtained a master's degree in immunology from Shanghai Fudan University School of Medicine and a Ph.D. in immunology from King’s College, University of London. He has taught at the University of Maryland School of Medicine and Duke University Medical Center in the United States. He then worked at Baylor College of Medicine as a tenured professor in the Department of Pathology and Immunology. He was responsible for immunology research at the GlaxoSmithKline R&D center. He served as the Global Vice President of Janssen Pharmaceuticals, Johnson & Johnson, leading innovative drug development in the field of immunology in the Asia-Pacific region, including immune regulation mechanisms, cancer immunology, and autoimmune diseases.

Professor Zheng Biao has a wealth of academic publications, many of which have been published in world-renowned journals such as Nature and Science. During his tenure at the University of Maryland, Duke University, and Baylor College of Medicine, he received numerous significant research grants, including funding from the U.S. NIH, the Leukemia & Lymphoma Society, the Arthritis Foundation, the American Heart Association, and the Alliance for Aging Research. In drug development, he has accumulated important experience in areas such as new drug screening, target research, disease models, preclinical and clinical trials, and has a deep understanding of the entire process of new drug development. He has extensive experience in developing small molecule drugs, large molecule antibody drugs, and cell therapy pipelines.

Course Outline

1. Review and Progress of Gene Editing Technology

2. Clinical Application of Gene and Cell Therapy in Hematological Disorders

3. The Mechanism of Gene Therapy in Treating Thalassemia

4. BRL Medicine's BRL-101 in the Clinical Study for Treating Severe β-Thalassemia

Live Broadcast Reservation

July 24th, 19:30-21:00

Clinical Translation Study of Gene-Edited Hematopoietic Stem Cells for the Treatment of β-Thalassemia